Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
HER2-Positive Cancers
Sort By
Newest First
Sign in
1 / 1
1 / 1
FDA
Boehringer's Zongertinib ReceivesFDA Priority Review for the Treatment of HER2 (ERBB2)- NSCLC
Boehringer Ingelheim Pharmaceuticals, Inc.
PR-02-25-NI-21
Feb 20, 2025
Clinical Trials
EXUMA Biotech Announces Phase 1 Results for its Autologous HER2 Directed CAR-T Product at ASCO GI 2025
EXUMA Biotechnology
PR-01-25-NI-26
Feb 11, 2025
Agreement
Glenmark Pharmaceuticals and Harbour BioMed Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers
Glenmark Pharmaceuticals
PR-M08-18-NI-050
Aug 13, 2018
